What is the long-term trend for Ligand Pharmaceuticals's finance lease, principal payments?

Over 3 years (2022 to 2025), Ligand Pharmaceuticals's finance lease, principal payments has grown at a -20.6% compound annual growth rate (CAGR), from $54K to $27K.

Ligand Pharmaceuticals LGND Finance Lease, Principal Payments

Finance Lease, Principal Payments at other companies

LQD

Liquidia CorporationLQDA

——

Roivant SciencesROIV

——

IncyteINCY

——

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.6B+96.7%

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's finance lease, principal payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's finance lease, principal payments?: Ligand Pharmaceuticals (LGND) reported finance lease, principal payments of $7K in Q1 2026.
How has Ligand Pharmaceuticals's finance lease, principal payments changed year-over-year?: Ligand Pharmaceuticals's finance lease, principal payments decreased by 0.0% year-over-year, from $7K to $7K.
What is the long-term trend for Ligand Pharmaceuticals's finance lease, principal payments?: Over 3 years (2022 to 2025), Ligand Pharmaceuticals's finance lease, principal payments has grown at a -20.6% compound annual growth rate (CAGR), from $54K to $27K.